SGMO
Sangamo Therapeutics, IncCompany with tickers: SGMO
CIK
1001233
CUSIP
800677106
Shares Outstanding
414,288,847
13F Activity (30d)
85 filings
85 filers
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $1,442,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $33,388,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $26,570,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-31,946,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-30,995,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $-0.08 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $-0.08 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |